PHARMARON (03759) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 6.441 billion, representing a year-on-year increase of 14.93%. Shareholders' profit attributable to the company totaled RMB 701 million, down 37% compared to the same period last year. Basic earnings per share stood at RMB 0.3984.

The company stated that despite the continued positive performance of its core business operations during the reporting period, net profit attributable to shareholders of the listed company reached RMB 701 million. The 37.0% decline compared to the same period last year was primarily due to the substantial investment gains generated from the disposal of PROTEOLOGIX, INC. equity in the corresponding period of the previous year.